Urolithin A vs. Osteoarthritis

Degenerative diseases, specifically those that affect joints and muscle, produce detrimental effects on movement, agility, strength, and quality of life. Numerous nutritional and strength exercise therapies focus on the regeneration of these tissues, mostly slowing the disease progression by modulating inflammatory response. Nowadays, osteoarthritis (OA) affects tens of millions worldwide and associates with joint degradation, loss of articular cartilage, and synovial inflammation. Indeed, OA is a multifactorial condition coinciding with aging, obesity, injury, and joint malformation. Urolithin A, a microbiome-derived metabolite, is associated with powerful anti-inflammatory effects and anti-aging benefits. Let’s find out what the studies say about reversing and preventing OA with UA supplementation. 

OA physiopathology:

Inflammation plays a central part in OA physiopathology. Indeed, studies suggest that elevated levels of pro-inflammatory mediators IL-1b, IL-6, and tumor necrosis factor-alpha (TNF-a) are found in OA cartilage. In addition, extensive research proves that IL-1b is a potent inflammatory response initiator and acts as a master regulator of the inflammatory cascade. 

Furthermore, an IL-1b upregulation stimulated the production of metalloproteinases (MMPs) by chondrocytes. In this pro-inflammatory environment, the combination of MMPs and thrombospondin type 1 motifs (ADAMTS), along with the presence of cyclooxygenase-2 (COX-2) and nitric oxide synthase (iNOS). Combining these factors results in cartilage alteration, promotes tissue catabolism, and promotes extracellular matrix (ECM) degradation.

UA vs. inflamm-aging

Low-grade inflammation is the continuous exposure of chronic inflammation. This factor is consistent with chronic degenerative diseases and age-related cellular decline resulting in organ and tissue dysfunction.

 

Several studies using animal models report consistent inflammatory modulatory effects of UA and its metabolic responses. Firstly, UA supplementation can reduce the expression of mRNA and circulatory levels of pro-inflammatory marker cyclooxygenase- 2 in rat models with acute colitis. Following studies in rat models associated UA with reduced inflammatory response inducer IL-1b, resulting in decreased concentration of IL-6 and TNF-A. On the contrary, an elevation of the anti-inflammatory cytokine IL-10 was observed in UA- treated diabetic mice.  

UA mechanism of action in joint disorders 

Between the anti-inflammatory mechanisms mediated by UA, the inhibition of TNF-a at a nuclear level of pulpous cells and the reduction of intervertebral disc degradation have been demonstrated in vivo.

A recent study performed in human chondrocytes intervened with UA demonstrated the anti-inflammatory orchestra of this microbiome-derived metabolite. Some of the mechanisms of action were:

  • UA reduced the levels of MMP3 and MMP13 in previously IL-1b-treated chondrocytes. This effect was associated with an attenuation of the expression of iNOS and COX-2.
  • The decrease of MMP3 resulted in an increase in Collagen II and proteoglycan synthesis.
  • Another crucial benefit associated with UA was the upregulation of Sox-9. Furthermore, Sox-9 is a transcription factor that modulated Collagen II synthesis, the cornerstone of chondrocyte differentiation.
  • In conclusion, this study reported that UA could be used as a therapeutic agent due to its capacity to restore the balance between the cartilage matrix anabolism and catabolism.

 UA modulates MAPK and NF-kb pathways.

Mitogen-activated protein kinase (MAPK) and NF-kb pathways function as master regulators in the process of OA pathology. In a healthy environment, MAPK transmits cellular stimulation signals that induce cell proliferation, differentiation, transformation, and apoptosis. However, in a pro-inflammatory environment, three key members of this pathway can act as potent initiators of a pro-inflammatory cascade. Indeed, elevated concentrations of the extracellular regulated kinase (ERK), N-terminal kinase (JNK), and p38 are found in synovial tissue and cartilage lesion. This upregulation reflects in articular damage caused by a higher concentration of MMPs-induced by activating these three factors and IL-1b inflammatory milieu.

Furthermore, IL-1b can stimulate NF-kB activation and nuclear translocation, resulting in an elevated expression of iNOS and COX-2. Consequently, this cascade reaction catalyzes the NO, increasing MMPs, which attenuates collagen II and proteoglycan synthesis. 

Concurrently, the study performed by Shen-long et al. reported that UA intervention could potentially reduce lipopolysaccharide-induced inflammation. Ultimately, this mechanism would decrease the MAPK and NF-kB pathways and promote an anabolic environment in the joint tissues. However, the same authors report that more information is still to be elucidated on this topic, and further research is needed. 

The inflammatory mechanism that promotes osteoarthritis can be prevented, reversed, and treated. Although, we have to consider that inflammation can be enabled by excessive fat mass, elevated concentration on ROS, and dietary components. Therefore, treating this age-related condition can be supported by weight reduction therapy, proper physical exercise, and nutritional advice. Furthermore, nutritional treatment should include an anti-inflammatory diet that enables a beneficial microbiome that can promote the formation of UA.- Ana Paola Rodríguez Arciniega, MS.

References:

Ding, Sheng-Long et al. “Urolithin a attenuates IL-1β-induced inflammatory responses and cartilage degradation via inhibiting the MAPK/NF-κB signaling pathways in rat articular chondrocytes.” Journal of inflammation (London, England) vol. 17 13. 24 Mar. 2020, doi:10.1186/s12950-020-00242-8

D’Amico, Davide et al. “Impact of the Natural Compound Urolithin A on Health, Disease, and Aging.” Trends in molecular medicine vol. 27,7 (2021): 687-699. doi:10.1016/j.molmed.2021.04.009

Additional Online Links & Resources (Available 24/7)

 

Online Appointments or Consultations: https://bit.ly/Book-Online-Appointment

 

Online Physical Injury / Accident Intake Form: https://bit.ly/Fill-Out-Your-Online-History 

 

Online Functional Medicine Assessment: https://bit.ly/functionmed

Post Disclaimer

Clinical Scope of Practice *

The information herein on " Urolithin A vs. Osteoarthritis " is not intended to replace a one-on-one relationship with a qualified health care professional, licensed physician, and is not medical advice. We encourage you to make your own health care decisions based on your research and partnership with a qualified health care professional. Our information scope is limited to chiropractic, musculoskeletal, physical medicines, wellness, sensitive health issues, functional medicine articles, topics, and discussions. We provide and present clinical collaboration with specialists from a wide array of disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for the injuries or disorders of the musculoskeletal system. Our videos, posts, topics, subjects, and insights cover clinical matters, issues, and topics that relate to and support, directly or indirectly, our clinical scope of practice.* Our office has made a reasonable attempt to provide supportive citations and has identified the relevant research study or studies supporting our posts. We provide copies of supporting research studies available to regulatory boards and the public upon request.

We understand that we cover matters that require an additional explanation of how it may assist in a particular care plan or treatment protocol; therefore, to further discuss the subject matter above, please feel free to ask Dr. Alex Jimenez or contact us at 915-850-0900.

Dr. Alex Jimenez DC, MSACP, CCST, IFMCP*, CIFM*, ATN*

email: coach@elpasofunctionalmedicine.com

phone: 915-850-0900

Licensed in: Texas & New Mexico*

What's your reaction?